IP Library Patent Application 13808080
Patent Application
App. No. 13/808,080

LIPOSOMES WITH LIPIDS HAVING AN ADVANTAGEOUS PKA-VALUE FOR RNA DELIVERY

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
13/808,080
Abstract

RNA encoding an immunogen is delivered in a liposome for the purposes of immunisation. The liposome includes lipids which have a pKa in the range of 5.0 to 7.6 and, preferably, a tertiary amine. These liposomes can have essentially neutral surface charge at physiological pH and are effective for immunisation.

Claims (14)

1 . A liposome having a lipid bilayer encapsulating an aqueous core, wherein: (i) the lipid bilayer comprises a lipid having a pKa in the range of 5.0 to 7.6; and (ii) the aqueous core includes a RNA which encodes an immunogen.

2 . The liposome of claim 1 , wherein the lipid having a pKa in the range of 5.0 to 7.6 has a tertiary amine.

3 . The liposome of claim 1 , wherein pKa in the range of 5.0 to 7.6 is between 5.7-5.9.

4 . The liposome of claim 1 , wherein the lipid having a pKa in the range of 5.0 to 7.6 has the formula shown herein for RV01, RV02, RV03, RV04, RV05, RV06, RV07, RV08, RV09, RV11, RV12, RV16 or RV17.

5 . The liposome of claim 1 , having a diameter in the range of 20-220 nm.

6 . The liposome of claim 1 , wherein the RNA molecule encodes (i) a RNA-dependent RNA polymerase which can transcribe RNA from the RNA molecule and (ii) an immunogen.

7 . The liposome of claim 5 , wherein the RNA molecule has two open reading frames, the first of which encodes an alphavirus replicase and the second of which encodes the immunogen.

8 . The liposome of claim 1 , wherein the RNA molecule is 9000-12000 nucleotides long.

9 . The liposome of claim 1 , wherein the immunogen can elicit an immune response in vivo against a bacterium, a virus, a fungus or a parasite.

10 . The liposome of claim 1 , wherein the immunogen can elicit an immune response in vivo against respiratory syncytial virus glycoprotein F.

11 . A pharmaceutical composition comprising the liposome of claim 1 .

12 . A method for raising a protective immune response in a vertebrate, comprising the step of administering to the vertebrate an effective amount of the liposome of claim 1 .

13 . A process for preparing a RNA-containing liposome, comprising steps during liposome formation of: (a) mixing RNA with a lipid at a pH which is below the lipid's pKa but is above 4.5; then (b) increasing the pH to be above the lipid's pKa.

14 . The process of claim 13 , wherein: RNA used in step (a) is in aqueous solution, for mixing with an organic solution of the lipid to give a mixture which is then diluted to form liposomes; and the pH is increased in step (b) after liposome formation.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 22, 2016
From: NOVARTIS AG
To: GLAXOSMITHKLINE BIOLOGICALS SA
Reel/Frame 038983/0004 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 3, 2013
From: GEALL, ANDREW
To: NOVARTIS VACCINES AND DIAGNOSTICS, INC.
Reel/Frame 030141/0269 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 3, 2013
From: NOVARTIS VACCINES AND DIAGNOSTICS, INC.
To: NOVARTIS AG
Reel/Frame 030141/0378 →